冀衡医药(002742)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

002742 冀衡医药

已收盘 08-20 15:00:00

{"stockData":{"symbol":"002742","market":"SZ","secType":"STK","nameCN":"冀衡医药","latestPrice":4.34,"timestamp":1787209437000,"preClose":4.29,"halted":0,"volume":66903843,"delay":0,"changeRate":0.0117,"floatShares":524000000,"shares":684000000,"eps":-0.4515,"marketStatus":"已收盘","change":0.05,"latestTime":"08-20 15:00:00","open":4.25,"high":4.72,"low":4.25,"amount":302000000,"amplitude":0.1096,"askPrice":4.34,"askSize":1834,"bidPrice":4.33,"bidSize":1411,"shortable":0,"etf":0,"ttmEps":-0.4515,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1787275800000},"marketStatusCode":5,"adr":0,"adjPreClose":4.29,"symbolType":"stock","openAndCloseTimeList":[[1787189400000,1787196600000],[1787202000000,1787209200000]],"highLimit":4.72,"lowLimit":3.86,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":684102041,"isCdr":false,"pbRate":19.8,"roa":"--","roe":"--","epsLYR":-0.61,"committee":0.355883,"marketValue":2969000000,"turnoverRate":0.1277,"status":0,"floatMarketCap":2274000000},"requestUrl":"/m/hq/s/002742/wiki","defaultTab":"wiki","newsList":[{"id":"2660876108","title":"股市必读：冀衡医药中报 - 第二季度单季净利润同比增长75.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660876108","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660876108?lang=zh_cn&edition=full","pubTime":"2026-08-17 03:13","pubTimestamp":1786907591,"startTime":"0","endTime":"0","summary":"股本股东变化：截至2026年7月31日股东户数为1.6万户，较6月30日增加5.98%。业绩披露要点：2026年上半年归母净利润为-2013.85万元，同比上升84.62%；第二季度单季度归母净利润-1206.52万元，同比上升75.18%。公司公告汇总：第六届董事会第五次会议于2026年8月14日审议通过《关于公司2026年半年度报告及报告摘要的议案》，表决结果为全票通过。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081700001187.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002742"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659179552","title":"冀衡医药（002742）2026年中报简析：亏损收窄","url":"https://stock-news.laohu8.com/highlight/detail?id=2659179552","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659179552?lang=zh_cn&edition=full","pubTime":"2026-08-16 06:05","pubTimestamp":1786831551,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期冀衡医药发布2026年中报。根据财报显示，冀衡医药亏损收窄。其中，毛利率12.1%，同比减40.69%，净利率-8.61%，同比增68.09%，销售费用、管理费用、财务费用总计3801.79万元，三费占营收比15.79%，同比减62.18%，每股净资产0.22元，同比增117.03%，每股经营性现金流-0.1元，同比减691.05%，每股收益-0.03元，同比增90.3%证券之星价投圈财报分析工具显示：业务评价：去年的净利率为-50.99%，算上全部成本后，公司产品或服务的附加值不高。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081600001377.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","BK0028","BK0235","002742"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659839140","title":"冀衡医药（002742）披露2026年半年度报告，8月14日股价下跌1.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=2659839140","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659839140?lang=zh_cn&edition=full","pubTime":"2026-08-14 22:35","pubTimestamp":1786718118,"startTime":"0","endTime":"0","summary":"截至2026年8月14日收盘，冀衡医药报收于4.27元，较前一交易日下跌1.84%，最新总市值为29.21亿元。该股当日开盘4.35元，最高4.53元，最低4.23元，成交额达9032.7万元，换手率为3.98%。近日，冀衡医药披露《2026年半年度报告》。本报告期末总资产为1,095,343,325.32元，较上年度末的1,195,759,012.89元下降8.40%；归属于上市公司股东的净资产为148,242,087.28元，较上年度末的168,380,544.20元下降11.96%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081400040723.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0235","BK0028","002742","BK0132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659614562","title":"冀衡医药(002742.SZ)发布上半年业绩，归母净亏损2013.85万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2659614562","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659614562?lang=zh_cn&edition=full","pubTime":"2026-08-14 19:14","pubTimestamp":1786706074,"startTime":"0","endTime":"0","summary":"智通财经APP讯，冀衡医药(002742.SZ)发布2026年半年度报告，报告期内，公司实现营业收入2.41亿元，同比下降50.51%。归属于上市公司股东净亏损2013.85万元，归属于上市公司股东的扣除非经常性损益净亏损1983.51万元，基本每股亏损0.0294元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1480194.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002742","BK0235","BK0132","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659897110","title":"图解冀衡医药中报：第二季度单季净利润同比增长75.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2659897110","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659897110?lang=zh_cn&edition=full","pubTime":"2026-08-14 17:40","pubTimestamp":1786700448,"startTime":"0","endTime":"0","summary":"证券之星消息，冀衡医药2026年中报显示，上半年度公司主营收入2.41亿元，同比下降50.51%；归母净利润-2013.85万元，同比上升84.62%；扣非净利润-1983.51万元，同比上升84.37%；其中2026年第二季度，公司单季度主营收入9881.57万元，同比下降60.7%；单季度归母净利润-1206.52万元，同比上升75.18%；单季度扣非净利润-1138.66万元，同比上升75.3%；负债率80.05%，投资收益-126.66万元，财务费用875.8万元，毛利率12.1%。财报数据概要请见下图:本文数据来源于冀衡医药2026年中报，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081400029864.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002742"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659117247","title":"冀衡医药(002742)7月31日股东户数1.6万户，较上期增加5.98%","url":"https://stock-news.laohu8.com/highlight/detail?id=2659117247","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659117247?lang=zh_cn&edition=full","pubTime":"2026-08-14 17:31","pubTimestamp":1786699912,"startTime":"0","endTime":"0","summary":"证券之星消息，近日冀衡医药披露，截至2026年7月31日公司股东户数为1.6万户，较6月30日增加903.0户，增幅为5.98%。在化学制药行业个股中，冀衡医药股东户数低于行业平均水平，截至7月31日，化学制药行业平均股东户数为3.61万户。从股价来看，2026年6月30日至2026年7月31日，冀衡医药区间涨幅为4.48%，在此期间股东户数增加903.0户，增幅为5.98%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081400029578.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","002742","BK0132","BK0235"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658099977","title":"冀衡医药：截至2026年7月31日，公司股东数为15,995户","url":"https://stock-news.laohu8.com/highlight/detail?id=2658099977","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658099977?lang=zh_cn&edition=full","pubTime":"2026-08-12 20:48","pubTimestamp":1786538900,"startTime":"0","endTime":"0","summary":"证券之星消息，冀衡医药(002742)08月12日在投资者关系平台上答复投资者关心的问题。投资者提问：请问截止到7月31日公司股东人数是多少？谢谢冀衡医药回复：尊敬的投资者，截至2026年7月31日，公司股东数为15,995户，感谢关注。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081200037916.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0235","002742","BK0132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654064250","title":"股市必读：冀衡医药（002742）7月24日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2654064250","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654064250?lang=zh_cn&edition=full","pubTime":"2026-07-27 02:30","pubTimestamp":1785090633,"startTime":"0","endTime":"0","summary":"截至2026年7月24日收盘，冀衡医药报收于3.27元，下跌3.82%，换手率1.26%，成交量6.58万手，成交额2167.16万元。董秘最新回复投资者： 董秘，你好！重组计划承诺2026年冀衡集团对冀衡医药支持2亿元用生产升级及闲置资产利用，已经快进入8月份了，不知道这2亿元用的怎么样，是否已经开始投入使用？目前，控股股东已向公司全资子公司提供了5000万元的低息借款支持其生产经营，感谢关注。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072700001186.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0235","BK0028","002742","BK0132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653082744","title":"冀衡医药：控股股东已提供5000万元低息借款","url":"https://stock-news.laohu8.com/highlight/detail?id=2653082744","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653082744?lang=zh_cn&edition=full","pubTime":"2026-07-24 20:52","pubTimestamp":1784897562,"startTime":"0","endTime":"0","summary":"证券之星消息，冀衡医药(002742)07月24日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘，你好！重组计划承诺2026年冀衡集团对冀衡医药支持2亿元用生产升级及闲置资产利用，已经快进入8月份了，不知道这2亿元用的怎么样，是否已经开始投入使用？冀衡医药回复：尊敬的投资者，根据《重整计划》，公司控股股东3年内将通过股东借款、非公开发行等方式为公司提供不少于2亿元现金流支持。目前，控股股东已向公司全资子公司提供了5000万元的低息借款支持其生产经营，感谢关注。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072400039698.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0235","002742","BK0028","BK0132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651448560","title":"股市必读：冀衡医药（002742）预计2026年1-6月扣非后净利润亏损1800万元至2300万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2651448560","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651448560?lang=zh_cn&edition=full","pubTime":"2026-07-15 02:42","pubTimestamp":1784054531,"startTime":"0","endTime":"0","summary":"截至2026年7月14日收盘，冀衡医药报收于3.59元，上涨1.41%，换手率1.7%，成交量8.9万手，成交额3153.85万元。业绩披露要点业绩预告冀衡医药发布业绩预告，预计2026年1-6月扣非后净利润亏损1800万元至2300万元；归属净利润亏损1800万元至2300万元；每股收益亏损0.029元至0.03元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071500002905.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002742"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651047511","title":"冀衡医药（002742）披露2026年半年度业绩预告，7月14日股价上涨1.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2651047511","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651047511?lang=zh_cn&edition=full","pubTime":"2026-07-14 22:38","pubTimestamp":1784039894,"startTime":"0","endTime":"0","summary":"截至2026年7月14日收盘，冀衡医药报收于3.59元，较前一交易日上涨1.41%，最新总市值为24.56亿元。该股当日开盘3.52元，最高3.6元，最低3.45元，成交额达3153.85万元，换手率为1.7%。公告显示，公司预计2026年上半年归属于上市公司股东的净利润为-2,300万元至-1,800万元，较上年同期亏损大幅收窄。相关财务数据未经会计师事务所审计，最终数据以2026年半年度报告为准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071400049830.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","002742","BK0235","BK0132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646735684","title":"冀衡医药：6月26日副总经理高序英增持股份合计5.2万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2646735684","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2646735684?lang=zh_cn&edition=full","pubTime":"2026-06-26 18:01","pubTimestamp":1782468089,"startTime":"0","endTime":"0","summary":"证券之星消息，根据6月26日市场公开信息、上市公司公告及交易所披露数据整理，冀衡医药（002742）最新董监高及相关人员股份变动情况：2026年6月26日公司副总经理高序英共增持公司股份5.2万股，占公司总股本为0.0076%。变动期间公司股价下跌4.12%，6月26日当日收盘报3.26元。冀衡医药近半年内的董监高及核心技术人员增减持详情如下：冀衡医药的高管列表及最新持股情况如下：该股最近90天内无机构评级。本文数据来源于深圳证券交易所信息披露、冀衡医药公告，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062600033900.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","002742","BK0132","BK0235"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645022099","title":"冀衡医药：公司目前暂未开展市值管理相关工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2645022099","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2645022099?lang=zh_cn&edition=full","pubTime":"2026-06-22 20:48","pubTimestamp":1782132485,"startTime":"0","endTime":"0","summary":"证券之星消息，冀衡医药(002742)06月22日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘，你好 公司有没有做市值管理的预期？现在股价一路下跌，公司有没有什么应对方案？冀衡医药回复：尊敬的投资者，公司目前暂未开展市值管理相关工作，自重整完成后，公司管理层致力于资产剥离、资产过户等重整相关的后续工作，同时积极开展子公司整合资源、产销优化、生产线技改等夯实主业的工作，近期股价波动较大，敬请投资者注意投资风险，感谢关注。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062200036201.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0235","002742","BK0132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645998950","title":"每周股票复盘：冀衡医药（002742）因日跌幅偏离值达7%上榜龙虎榜","url":"https://stock-news.laohu8.com/highlight/detail?id=2645998950","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2645998950?lang=zh_cn&edition=full","pubTime":"2026-06-21 03:46","pubTimestamp":1781984772,"startTime":"0","endTime":"0","summary":"截至2026年6月18日收盘，冀衡医药报收于3.58元，较上周的4.17元下跌14.15%。本周，冀衡医药6月15日盘中最高价报4.59元。6月18日盘中最低价报3.45元，股价触及近一年最低点。冀衡医药当前最新总市值24.49亿元，在化学制药板块市值排名136/150，在两市A股市值排名4723/5206。本周关注点来自交易信息汇总：冀衡医药因日跌幅偏离值达到7%的前5只证券登上龙虎榜。此次是近5个交易日内第1次上榜。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062100001301.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002742","BK0028","BK0235","BK0132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644712248","title":"6月17日冀衡医药（002742）龙虎榜数据：机构净卖出307.79万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2644712248","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2644712248?lang=zh_cn&edition=full","pubTime":"2026-06-17 17:31","pubTimestamp":1781688712,"startTime":"0","endTime":"0","summary":"证券之星消息，沪深交易所2026年6月17日公布的交易公开信息显示，冀衡医药因日跌幅偏离值达到7%的前5只证券登上龙虎榜。此次是近5个交易日内第1次上榜。截至2026年6月17日收盘，冀衡医药报收于3.61元，下跌8.61%，换手率4.2%，成交量21.98万手，成交额8186.63万元。从龙虎榜公布的当日买卖数据来看，机构合计净卖出307.79万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061700030401.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","002742","BK0235","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642426256","title":"三圣股份：控股股东冀衡集团注入冀衡药业承诺依然有效","url":"https://stock-news.laohu8.com/highlight/detail?id=2642426256","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2642426256?lang=zh_cn&edition=full","pubTime":"2026-06-10 20:51","pubTimestamp":1781095914,"startTime":"0","endTime":"0","summary":"证券之星消息，三圣股份06月09日在投资者关系平台上答复投资者关心的问题。当前公司全称已变更为“重庆冀衡医药股份有限公司”，工商变更已完成，医药主业地位已确立。冀衡集团是否有评估“法规条件提前变化、可尽早推进”的机制？","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061000039975.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","BK0235","BK0028","002742"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638695571","title":"三圣股份：根据公司重整计划，海外资产已剥离","url":"https://stock-news.laohu8.com/highlight/detail?id=2638695571","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2638695571?lang=zh_cn&edition=full","pubTime":"2026-05-28 20:48","pubTimestamp":1779972496,"startTime":"0","endTime":"0","summary":"证券之星消息，三圣股份(002742)05月27日在投资者关系平台上答复投资者关心的问题。投资者提问：子公司春瑞医化生产的抗病毒药品中间体及埃塞俄比亚工厂的基础药物产能，是否具备为非洲埃博拉疫区生产或供应抗感染、对症治疗类药品的能力？未来是否会视非洲疫情发展，向埃塞俄比亚卫生部提供相关医疗物资支持？三圣股份回复：尊敬的投资者，根据公司重整计划，海外资产已剥离，感谢关注。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052800041002.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0235","BK0132","002742","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638695657","title":"三圣股份：公司变更名称及经营范围的申请及材料已向相关部门提交","url":"https://stock-news.laohu8.com/highlight/detail?id=2638695657","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2638695657?lang=zh_cn&edition=full","pubTime":"2026-05-28 20:48","pubTimestamp":1779972495,"startTime":"0","endTime":"0","summary":"证券之星消息，三圣股份(002742)05月27日在投资者关系平台上答复投资者关心的问题。投资者提问：从2026年4月29日股东大会通过更名议案至今（5月26日），已经过去27天。请问董秘公司已经跟工商局提交资料申请了吗？三圣股份回复：尊敬的投资者，公司变更名称及经营范围的申请及材料已向相关部门提交，感谢关注。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052800041000.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0132","002742","BK0235"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638695507","title":"三圣股份：拟筹建新项目提高资产使用率","url":"https://stock-news.laohu8.com/highlight/detail?id=2638695507","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2638695507?lang=zh_cn&edition=full","pubTime":"2026-05-28 20:48","pubTimestamp":1779972495,"startTime":"0","endTime":"0","summary":"证券之星消息，三圣股份05月27日在投资者关系平台上答复投资者关心的问题。三圣股份回复：尊敬的投资者，根据公司2026年1-3月订单量，与 2025 年订单量及实际生产销售情况对比，均有不同程度的上涨，生产经营秩序逐步恢复。按公司2026年经营计划，拟对下属子公司产能利用率不足的单位，筹建新项目，提高资产使用率，增加营业收入，降低成本；积极协调各合作银行办理授信，置换留债贷款，减少原留债贷款的担保费用。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052800040999.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","BK0028","BK0235","002742"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637327354","title":"股市必读：三圣股份（002742）5月21日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2637327354","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2637327354?lang=zh_cn&edition=full","pubTime":"2026-05-22 04:09","pubTimestamp":1779394152,"startTime":"0","endTime":"0","summary":"截至2026年5月21日收盘，三圣股份报收于4.42元，下跌3.91%，换手率1.9%，成交量9.97万手，成交额4524.08万元。董秘最新回复投资者： 你好，请问到5月20日为止，最新股东户数是多少？董秘： 尊敬的投资者，截至2026年5月20日，公司股东数为13,778户，感谢关注。当日关注点来自交易信息汇总：5月21日主力与游资资金均呈净流出，散户资金净流入501.37万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052200005312.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002742","BK0132","BK0235","BK0028"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1787263803532,"stockEarnings":[{"period":"1week","weight":-0.0023},{"period":"1month","weight":0.3112},{"period":"3month","weight":-0.0247},{"period":"6month","weight":0.0309},{"period":"1year","weight":-0.1001},{"period":"ytd","weight":-0.0398}],"compareEarnings":[{"period":"1week","weight":-0.0059},{"period":"1month","weight":0.0102},{"period":"3month","weight":-0.0509},{"period":"6month","weight":-0.0437},{"period":"1year","weight":0.0365},{"period":"ytd","weight":-0.0164}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"重庆冀衡医药股份有限公司","boardCode":"AI0030","boardName":"非金属矿物制品业","stockholders":"15995人(较上一季度增加5.98%)","perCapita":"32755股","listingDate":"2015-02-17","address":"重庆市北碚区三圣镇街道","registeredCapital":"68410万元","survey":"　　重庆冀衡医药股份有限公司的主营业务是医药制造业务。公司的主要产品是医药中间体、原料药、制剂产品。","listedPrice":20.37},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"冀衡医药(002742)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供冀衡医药(002742)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"冀衡医药,002742,冀衡医药股票,冀衡医药股票老虎,冀衡医药股票老虎国际,冀衡医药行情,冀衡医药股票行情,冀衡医药股价,冀衡医药股市,冀衡医药股票价格,冀衡医药股票交易,冀衡医药股票购买,冀衡医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"冀衡医药(002742)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供冀衡医药(002742)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}